Bibliography
- Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002;14:281-6
- Khana D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systemic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res(Hoboken) 2012;64:1431-46
- Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendation for gout. Part II: management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24
- Uloric® [package insert]. Takeda Pharmaceuticals America, Inc; Deerfield, IL: 2013
- Ramasamy SN, Korb-Wells CS, Kannangara DR, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf 2013;36:953-80
- Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol 2011;38:1957-9
- Gandhi PK, Gentry WM, Bottorff MB. Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database. Semin Arthritis Rheum 2013;42:562-6
- Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994;308:81-106
- Edwards NL. Febuxostat: a new treatment for hyperuricemia in gout. Rheumatology 2009;48(Suppl 2):ii15-19
- Becker MA, Schumacher HRJr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61
- Schumacher HRJr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, parallel-group trial. Arthritis Rheum 2008;59:1540-8
- Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12:R63
- Schumacher HRJr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-year findings of the FOCUS efficacy and safety study. Rheumatology 2009;48:188-94
- Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36:1273-82
- Ye P, Yang S, Zhang W, et al. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Clin Ther 2013;35:180-9
- U.S. Food and Drug Administration. Orange book: approved drug products with therapeutic equivalence evaluations. Available from: http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021856&Product_No=001&table1=OB_Rx [Accessed 17 September 2014]
- Mylan Pharmaceuticals, Inc. Mylan confirms first-to-file patent challenge relating to Uloric®. Available from: http://investor.mylan.com/releasedetail.cfm?ReleaseID=803768 [Accessed 17 September 2014]
- Clinicaltrials.gov. Efficacy and safety of extended release and immediate release febuxostat in participants with gout and moderate renal impairment. Available from: http://www.clinicaltrials.gov/show/NCT02128490 [Accessed 17 September 2014]